Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
NOVEL LRRK2 INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2022/216098
Kind Code:
A1
Abstract:
The present invention relates to: a novel leucine-rich repeat kinase 2 (LRRK2) inhibitor of chemical formula 1; a pharmaceutical composition for the prevention or treatment of diseases or disorders mediated by or associated with LRRK2, the pharmaceutical composition comprising same; and a method for treating and preventing diseases by using same. The compound according to the present invention has excellent LRRK2 inhibitory activity, and thus can be effectively used in the prevention or treatment of diseases or disorders (e.g., Parkinson's disease) mediated by or associated with LRRK2.

Inventors:
KANG EUNJI (KR)
SHIN JAE HONG (KR)
KIM HYUN JIN (KR)
LEE JAEYOUNG (KR)
CHO DAE HYUN (KR)
KO EUN (KR)
KIM SEUNG CHAN (KR)
SONG SANG OK (KR)
Application Number:
PCT/KR2022/005076
Publication Date:
October 13, 2022
Filing Date:
April 07, 2022
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
STANDIGM INC (KR)
International Classes:
C07D401/14; A61K31/506; A61K31/5377; A61P25/16; A61P25/28; C07D401/04; C07D401/12; C07D403/04; C07D403/14; C07D413/04
Domestic Patent References:
WO2021000884A12021-01-07
Foreign References:
KR20160145837A2016-12-20
KR101354114B12014-01-24
KR20180032784A2018-04-02
Other References:
LI YINGXIU; WANG PENG; CHEN CONG; YE TIANYU; HAN YUFEI; HOU YUNLEI; LIU YAJING; GONG PING; QIN MINGZE; ZHAO YANFANG: "Discovery and rational design of 2-aminopyrimidine-based derivatives targeting Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3)", BIOORGANIC CHEMISTRY, vol. 104, 1 November 2020 (2020-11-01), US , pages 1 - 16, XP086351369, ISSN: 0045-2068, DOI: 10.1016/j.bioorg.2020.104361
Attorney, Agent or Firm:
RYU, Jong Woo et al. (KR)
Download PDF: